Symbols / VTRS $14.52 -1.43% Viatris Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
VTRS Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Fundamentals
Scroll to Statements
Market Cap 16.91B Enterprise Value 29.90B Income -3.51B Sales 14.30B Book/sh 12.78 Cash/sh 1.31
Dividend Yield 3.31% Payout 9.60% Employees 30000 IPO — P/E — Forward P/E 5.45
PEG 0.15 P/S 1.18 P/B 1.14 P/C — EV/EBITDA 7.55 EV/Sales 2.09
Quick Ratio 0.69 Current Ratio 1.38 Debt/Eq 99.91 LT Debt/Eq — EPS (ttm) -3.00 EPS next Y 2.66
EPS Growth — Revenue Growth 5.00% Earnings 2026-05-07 ROA 1.96% ROE -21.08% ROIC —
Gross Margin 39.55% Oper. Margin 7.78% Profit Margin -24.58% Shs Outstand 1.16B Shs Float 1.14B Short Float 2.77%
Short Ratio 3.18 Short Interest — 52W High 16.47 52W Low 7.82 Beta 0.82 Avg Volume 10.28M
Volume 8.62M Target Price $15.72 Recom Buy Prev Close $14.73 Price $14.52 Change -1.43%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$15.72
Mean price target
2. Current target
$14.52
Latest analyst target
3. DCF / Fair value
$37.59
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$14.52
Low
$12.00
High
$20.00
Mean
$15.72

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 main Barclays Overweight → Overweight $17
2026-01-28 main Piper Sandler Neutral → Neutral $12
2026-01-16 up Argus Research Hold → Buy $15
2025-12-09 init Barclays — → Overweight $15
2025-10-15 init Truist Securities — → Buy $15
2025-06-06 init Goldman Sachs — → Neutral $10
2025-03-07 main Jefferies Buy → Buy $13
2025-03-05 reit Piper Sandler Neutral → Neutral $10
2025-02-28 main Barclays Underweight → Underweight $9
2025-02-28 main B of A Securities Underperform → Underperform $10
2024-12-06 reit Piper Sandler Neutral → Neutral $14
2024-11-08 main Barclays Underweight → Underweight $12
2024-03-28 reit Piper Sandler Neutral → Neutral $13
2023-11-22 main Piper Sandler Neutral → Neutral $11
2023-10-23 down B of A Securities Neutral → Underperform $9
2023-06-23 down Barclays Equal-Weight → Underweight $11
2023-04-25 down Barclays Overweight → Equal-Weight $11
2023-04-24 down Barclays Overweight → Equal-Weight $11
2023-02-28 main Barclays — → Overweight $16
2023-02-17 down BMO Capital Outperform → Market Perform $14
News
RSS: Latest VTRS news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
14,299.90
-2.98%
14,739.30
-4.46%
15,426.90
-5.14%
16,262.70
Operating Revenue
23,732.90
-4.71%
24,905.20
-3.07%
25,693.10
-7.12%
27,662.10
Cost Of Revenue
9,286.40
+1.87%
9,115.70
+1.42%
8,988.30
-7.96%
9,765.70
Reconciled Cost Of Revenue
9,286.40
+1.87%
9,115.70
+1.42%
8,988.30
-7.96%
9,765.70
Gross Profit
5,013.50
-10.85%
5,623.60
-12.66%
6,438.60
-0.90%
6,497.00
Operating Expense
4,760.00
-3.12%
4,913.30
+0.78%
4,875.20
+0.70%
4,841.30
Research And Development
965.90
+19.44%
808.70
+0.43%
805.20
+21.59%
662.20
Selling General And Administration
3,794.10
-7.56%
4,104.60
+0.85%
4,070.00
-2.61%
4,179.10
Total Expenses
14,046.40
+0.12%
14,029.00
+1.19%
13,863.50
-5.09%
14,607.00
Operating Income
253.50
-64.31%
710.30
-54.57%
1,563.40
-5.57%
1,655.70
Total Operating Income As Reported
-2,663.10
-26467.33%
10.10
-98.68%
766.20
-52.55%
1,614.90
EBITDA
-395.40
-114.02%
2,820.00
-19.81%
3,516.50
-45.34%
6,433.20
Normalized EBITDA
2,521.20
-28.38%
3,520.20
-18.39%
4,313.70
-33.37%
6,474.00
Reconciled Depreciation
2,798.30
-3.28%
2,893.20
+5.57%
2,740.50
-9.48%
3,027.60
EBIT
-3,193.70
-4262.98%
-73.20
-109.43%
776.00
-77.21%
3,405.60
Total Unusual Items
-2,916.60
-316.54%
-700.20
+12.17%
-797.20
-1853.92%
-40.80
Total Unusual Items Excluding Goodwill
-2,916.60
-316.54%
-700.20
+12.17%
-797.20
-1853.92%
-40.80
Special Income Charges
-2,916.60
-316.54%
-700.20
+12.17%
-797.20
-1853.92%
-40.80
Other Special Charges
131.20
-59.56%
324.40
+49.42%
217.10
+432.11%
40.80
Impairment Of Capital Assets
2,936.80
+814.89%
321.00
-44.66%
580.10
—
Restructuring And Mergern Acquisition
-151.40
-376.28%
54.80
-31.84%
80.40
+624.32%
11.10
Net Income
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Pretax Income
-3,665.00
-488.09%
-623.20
-407.15%
202.90
-92.79%
2,813.20
Net Non Operating Interest Income Expense
-471.30
+14.31%
-550.00
+4.03%
-573.10
+3.26%
-592.40
Interest Expense Non Operating
471.30
-14.31%
550.00
-4.03%
573.10
-3.26%
592.40
Net Interest Income
-471.30
+14.31%
-550.00
+4.03%
-573.10
+3.26%
-592.40
Interest Expense
471.30
-14.31%
550.00
-4.03%
573.10
-3.26%
592.40
Other Income Expense
-3,447.20
-339.97%
-783.50
+0.50%
-787.40
-145.00%
1,749.90
Other Non Operating Income Expenses
-530.60
-536.97%
-83.30
-950.00%
9.80
-99.45%
1,790.70
Tax Provision
-150.10
-1464.55%
11.00
-92.58%
148.20
-79.83%
734.60
Tax Rate For Calcs
0.00
-80.48%
0.00
+0.00%
0.00
-19.54%
0.00
Tax Effect Of Unusual Items
-119.58
+18.68%
-147.04
+12.17%
-167.41
-1472.12%
-10.65
Net Income Including Noncontrolling Interests
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Net Income From Continuing Operation Net Minority Interest
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Net Income From Continuing And Discontinued Operation
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Net Income Continuous Operations
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Normalized Income
-717.88
-785.81%
-81.04
-111.84%
684.49
-67.54%
2,108.75
Net Income Common Stockholders
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Diluted EPS
-3.00
-466.04%
-0.53
-1160.00%
0.05
-97.08%
1.71
Basic EPS
-3.00
-466.04%
-0.53
-1160.00%
0.05
-97.08%
1.71
Basic Average Shares
1,170.70
-1.89%
1,193.30
-0.58%
1,200.30
-0.97%
1,212.10
Diluted Average Shares
1,170.70
-1.89%
1,193.30
-1.13%
1,206.90
-0.86%
1,217.40
Diluted NI Availto Com Stockholders
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Line Item Trend 2025-12-31 2024-12-31 2023-12-31
Total Assets
37,193.10
-10.38%
41,500.90
-12.97%
47,685.50
Current Assets
9,789.20
+2.82%
9,520.70
-26.63%
12,976.10
Cash Cash Equivalents And Short Term Investments
1,513.00
+38.82%
1,089.90
-7.98%
1,184.40
Cash And Cash Equivalents
1,322.40
+79.97%
734.80
-25.92%
991.90
Other Short Term Investments
190.60
-46.32%
355.10
+84.47%
192.50
Receivables
3,347.10
-4.97%
3,522.00
-12.83%
4,040.60
Accounts Receivable
2,577.60
-3.65%
2,675.30
-5.26%
2,823.80
Gross Accounts Receivable
2,713.60
-2.49%
2,782.90
-5.43%
2,942.60
Allowance For Doubtful Accounts Receivable
-136.00
-26.39%
-107.60
+9.43%
-118.80
Other Receivables
453.70
-16.90%
546.00
-37.71%
876.60
Taxes Receivable
315.80
+5.02%
300.70
-11.61%
340.20
Inventory
3,999.20
+3.76%
3,854.10
+11.08%
3,469.70
Raw Materials
1,422.40
+5.68%
1,345.90
+83.94%
731.70
Work In Process
491.70
-6.75%
527.30
-12.42%
602.10
Finished Goods
2,085.10
+5.26%
1,980.90
-7.26%
2,135.90
Prepaid Assets
225.40
+59.97%
140.90
-9.62%
155.90
Current Deferred Assets
568.30
+7.92%
526.60
-50.72%
1,068.50
Assets Held For Sale Current
—
0.00
-100.00%
2,786.00
Other Current Assets
136.20
-64.82%
387.20
+42.88%
271.00
Total Non Current Assets
27,403.90
-14.31%
31,980.20
-7.86%
34,709.40
Net PPE
2,885.30
-1.16%
2,919.20
-2.86%
3,005.20
Gross PPE
5,406.00
+5.54%
5,122.40
+2.12%
5,015.90
Accumulated Depreciation
-2,520.70
-14.41%
-2,203.20
-9.57%
-2,010.70
Properties
0.00
0.00
0.00
Land And Improvements
114.90
+1.50%
113.20
-5.82%
120.20
Buildings And Improvements
1,527.90
+4.34%
1,464.30
+1.38%
1,444.40
Machinery Furniture Equipment
3,043.40
+5.14%
2,894.70
+4.33%
2,774.50
Construction In Progress
448.50
+12.94%
397.10
-7.91%
431.20
Other Properties
271.30
+7.19%
253.10
+3.05%
245.60
Goodwill And Other Intangible Assets
21,856.80
-16.59%
26,204.20
-9.79%
29,048.20
Goodwill
6,754.70
-26.04%
9,133.30
-7.44%
9,867.10
Other Intangible Assets
15,102.10
-11.53%
17,070.90
-11.00%
19,181.10
Investments And Advances
815.00
-39.62%
1,349.80
+18.20%
1,142.00
Long Term Equity Investment
—
—
—
Non Current Deferred Assets
1,061.20
+40.93%
753.00
+8.67%
692.90
Non Current Deferred Taxes Assets
1,061.20
+40.93%
753.00
+8.67%
692.90
Other Non Current Assets
785.60
+4.19%
754.00
-8.17%
821.10
Total Liabilities Net Minority Interest
22,481.80
-1.68%
22,865.40
-15.99%
27,218.10
Current Liabilities
7,094.30
+22.75%
5,779.40
-25.69%
7,777.40
Payables And Accrued Expenses
4,065.10
-6.58%
4,351.20
-0.04%
4,353.00
Payables
1,878.10
-8.22%
2,046.40
-5.48%
2,165.00
Accounts Payable
1,293.70
-4.55%
1,355.30
-1.89%
1,381.40
Other Payable
460.40
-7.62%
498.40
-10.49%
556.80
Current Accrued Expenses
2,187.00
-5.11%
2,304.80
+5.34%
2,188.00
Employee Benefits
425.90
-8.98%
467.90
-7.22%
504.30
Total Tax Payable
124.00
-35.65%
192.70
-15.04%
226.80
Income Tax Payable
124.00
-35.65%
192.70
-15.04%
226.80
Current Debt And Capital Lease Obligation
2,039.30
+2225.31%
87.70
-95.65%
2,017.70
Current Debt
1,929.90
+321550.00%
0.60
-99.97%
1,934.70
Other Current Borrowings
1,929.90
+321550.00%
0.60
-99.97%
1,934.70
Current Capital Lease Obligation
109.40
+25.60%
87.10
+4.94%
83.00
Other Current Liabilities
989.90
-26.15%
1,340.50
-4.71%
1,406.70
Total Non Current Liabilities Net Minority Interest
15,387.50
-9.94%
17,086.00
-12.11%
19,440.70
Long Term Debt And Capital Lease Obligation
12,658.70
-10.97%
14,218.20
-13.06%
16,353.50
Long Term Debt
12,480.60
-11.10%
14,038.90
-13.28%
16,188.10
Long Term Capital Lease Obligation
178.10
-0.67%
179.30
+8.40%
165.40
Tradeand Other Payables Non Current
332.60
-2.72%
341.90
-14.38%
399.30
Non Current Deferred Liabilities
892.00
-19.49%
1,107.90
-36.17%
1,735.70
Non Current Deferred Taxes Liabilities
892.00
-19.49%
1,107.90
-36.17%
1,735.70
Other Non Current Liabilities
962.00
+17.09%
821.60
+111.37%
388.70
Stockholders Equity
14,711.30
-21.06%
18,635.50
-8.95%
20,467.40
Common Stock Equity
14,711.30
-21.06%
18,635.50
-8.95%
20,467.40
Capital Stock
12.50
+1.63%
12.30
+0.82%
12.20
Common Stock
12.50
+1.63%
12.30
+0.82%
12.20
Share Issued
1,245.39
+0.91%
1,234.13
+0.99%
1,221.99
Ordinary Shares Number
1,151.22
-3.55%
1,193.65
-0.59%
1,200.75
Treasury Shares Number
94.18
+132.63%
40.48
+90.61%
21.24
Additional Paid In Capital
18,801.30
-0.64%
18,921.60
+0.57%
18,814.70
Retained Earnings
-388.30
-111.36%
3,418.80
-26.31%
4,639.70
Gains Losses Not Affecting Retained Earnings
-2,707.00
+15.75%
-3,212.90
-16.94%
-2,747.40
Treasury Stock
1,007.20
+99.72%
504.30
+100.28%
251.80
Other Equity Adjustments
-2,707.00
+15.75%
-3,212.90
-16.94%
-2,747.40
Total Equity Gross Minority Interest
14,711.30
-21.06%
18,635.50
-8.95%
20,467.40
Total Capitalization
27,191.90
-16.78%
32,674.40
-10.86%
36,655.50
Working Capital
2,694.90
-27.97%
3,741.30
-28.03%
5,198.70
Invested Capital
29,121.80
-10.87%
32,675.00
-15.33%
38,590.20
Total Debt
14,698.00
+2.74%
14,305.90
-22.13%
18,371.20
Net Debt
13,088.10
-1.63%
13,304.70
-22.34%
17,130.90
Capital Lease Obligations
287.50
+7.92%
266.40
+7.25%
248.40
Net Tangible Assets
-7,145.50
+5.59%
-7,568.70
+11.79%
-8,580.80
Tangible Book Value
-7,145.50
+5.59%
-7,568.70
+11.79%
-8,580.80
Available For Sale Securities
815.00
-39.62%
1,349.80
+18.20%
1,142.00
Commercial Paper
—
—
—
Current Deferred Taxes Assets
568.30
+7.92%
526.60
-29.53%
747.30
Current Notes Payable
—
—
—
Current Provisions
—
—
—
Dueto Related Parties Current
—
—
23.80
Foreign Currency Translation Adjustments
—
—
—
Interest Payable
52.90
+6.01%
49.90
-25.30%
66.80
Investmentin Financial Assets
815.00
-39.62%
1,349.80
+18.20%
1,142.00
Line Of Credit
—
—
—
Minimum Pension Liabilities
—
—
—
Non Current Accrued Expenses
116.30
-9.49%
128.50
+117.06%
59.20
Unrealized Gain Loss
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
2,315.90
+0.56%
2,302.90
-20.59%
2,900.00
-3.30%
2,999.00
Cash Flow From Continuing Operating Activities
2,315.90
+0.56%
2,302.90
-20.59%
2,900.00
-3.30%
2,999.00
Net Income From Continuing Operations
-3,514.90
-454.23%
-634.20
-1259.41%
54.70
-97.37%
2,078.60
Depreciation Amortization Depletion
2,798.30
-3.28%
2,893.20
+5.57%
2,740.50
-9.48%
3,027.60
Depreciation And Amortization
2,798.30
-3.28%
2,893.20
+5.57%
2,740.50
-9.48%
3,027.60
Other Non Cash Items
929.10
+269.86%
251.20
+146.03%
102.10
-76.40%
432.60
Stock Based Compensation
177.70
+21.63%
146.10
-19.15%
180.70
+55.24%
116.40
Asset Impairment Charge
2,936.80
+814.89%
321.00
-44.66%
580.10
—
Deferred Tax
-476.50
+37.92%
-767.60
-98.30%
-387.10
-1394.59%
-25.90
Deferred Income Tax
-476.50
+37.92%
-767.60
-98.30%
-387.10
-1394.59%
-25.90
Operating Gains Losses
151.80
-63.14%
411.80
+21.01%
340.30
+119.93%
-1,707.70
Gain Loss On Sale Of PPE
50.80
+313.01%
12.30
-87.75%
100.40
+116.38%
46.40
Change In Working Capital
-686.40
-115.44%
-318.60
+55.21%
-711.30
+22.90%
-922.60
Change In Receivables
334.60
+11.50%
300.10
+281.81%
78.60
+132.71%
-240.30
Changes In Account Receivables
334.60
+11.50%
300.10
+281.81%
78.60
+132.71%
-240.30
Change In Inventory
-106.40
+85.29%
-723.40
-17.95%
-613.30
-136.34%
-259.50
Change In Payables And Accrued Expense
-168.00
-566.67%
36.00
-88.56%
314.70
+84.90%
170.20
Change In Payable
-168.00
-566.67%
36.00
-88.56%
314.70
+84.90%
170.20
Change In Account Payable
-168.00
-566.67%
36.00
-88.56%
314.70
+84.90%
170.20
Change In Other Working Capital
-746.60
-1186.75%
68.70
+113.98%
-491.30
+17.15%
-593.00
Investing Cash Flow
-427.70
-123.75%
1,800.70
+308.29%
-864.50
-158.65%
1,474.10
Cash Flow From Continuing Investing Activities
-427.70
-123.75%
1,800.70
+308.29%
-864.50
-158.65%
1,474.10
Net PPE Purchase And Sale
34.90
+1192.59%
2.70
-80.71%
14.00
+1.45%
13.80
Sale Of PPE
34.90
+1192.59%
2.70
-80.71%
14.00
+1.45%
13.80
Capital Expenditure
-465.10
-29.52%
-359.10
+37.54%
-574.90
-17.47%
-489.40
Capital Expenditure Reported
-378.80
-16.20%
-326.00
+13.53%
-377.00
+7.14%
-406.00
Net Investment Purchase And Sale
0.00
0.00
0.00
+100.00%
-0.30
Purchase Of Investment
-23.90
+8.08%
-26.00
+1.14%
-26.30
+12.91%
-30.20
Sale Of Investment
23.90
-8.08%
26.00
-1.14%
26.30
-12.04%
29.90
Net Business Purchase And Sale
0.00
+100.00%
-350.00
+47.58%
-667.70
0.00
Purchase Of Business
0.00
+100.00%
-350.00
+47.58%
-667.70
0.00
Gain Loss On Sale Of Business
101.00
-74.72%
399.50
+66.53%
239.90
+113.68%
-1,754.10
Net Intangibles Purchase And Sale
-86.30
-160.73%
-33.10
+83.27%
-197.90
-137.29%
-83.40
Purchase Of Intangibles
-86.30
-160.73%
-33.10
+83.27%
-197.90
-137.29%
-83.40
Net Other Investing Changes
2.50
-99.90%
2,507.10
+588.57%
364.10
-81.33%
1,950.00
Financing Cash Flow
-1,293.90
+70.12%
-4,330.40
-88.12%
-2,301.90
+40.64%
-3,877.90
Cash Flow From Continuing Financing Activities
-1,293.90
+70.12%
-4,330.40
-88.12%
-2,301.90
+40.64%
-3,877.90
Net Issuance Payments Of Debt
0.10
+100.00%
-3,713.70
-197.19%
-1,249.60
+61.90%
-3,280.10
Issuance Of Debt
0.00
0.00
-100.00%
0.30
-99.98%
1,875.60
Repayment Of Debt
-0.10
+100.00%
-3,713.70
-197.05%
-1,250.20
+65.86%
-3,662.50
Long Term Debt Issuance
0.00
0.00
-100.00%
0.30
-99.98%
1,875.60
Long Term Debt Payments
-0.10
+100.00%
-3,713.70
-197.05%
-1,250.20
+65.86%
-3,662.50
Net Long Term Debt Issuance
-0.10
+100.00%
-3,713.70
-197.12%
-1,249.90
+30.05%
-1,786.90
Net Short Term Debt Issuance
0.20
0.00
-100.00%
0.30
+100.02%
-1,493.20
Net Common Stock Issuance
-497.90
-101.17%
-247.50
-0.24%
-246.90
-7581.82%
3.30
Common Stock Payments
-500.50
-100.20%
-250.00
+0.00%
-250.00
0.00
Common Stock Dividend Paid
-561.20
+2.37%
-574.80
+0.14%
-575.60
+1.03%
-581.60
Cash Dividends Paid
-561.20
+2.37%
-574.80
+0.14%
-575.60
+1.03%
-581.60
Repurchase Of Capital Stock
-500.50
-100.20%
-250.00
+0.00%
-250.00
0.00
Proceeds From Stock Option Exercised
—
—
—
0.00
Net Other Financing Charges
-234.90
-214.25%
205.60
+189.47%
-229.80
-1078.46%
-19.50
Changes In Cash
594.30
+362.04%
-226.80
+14.86%
-266.40
-144.76%
595.20
Effect Of Exchange Rate Changes
17.60
+157.33%
-30.70
-1128.00%
-2.50
+93.57%
-38.90
Beginning Cash Position
736.10
-25.92%
993.60
-21.30%
1,262.50
+78.77%
706.20
End Cash Position
1,348.00
+83.13%
736.10
-25.92%
993.60
-21.30%
1,262.50
Free Cash Flow
1,850.80
-4.78%
1,943.80
-16.40%
2,325.10
-7.35%
2,509.60
Interest Paid Supplemental Data
492.60
-12.21%
561.10
-8.26%
611.60
-4.81%
642.50
Income Tax Paid Supplemental Data
—
514.00
-9.97%
570.90
-22.35%
735.20
Common Stock Issuance
2.60
+4.00%
2.50
-19.35%
3.10
-6.06%
3.30
Earnings Losses From Equity Investments
—
—
0.00
0.00
Issuance Of Capital Stock
2.60
+4.00%
2.50
-19.35%
3.10
-6.06%
3.30
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category